This concept covers evidence-based decision-making principles in breast cancer oncology: the use of validated genomic recurrence-risk assays (multi-gene expression assays) to stratify which patients derive meaningful benefit from adding chemotherapy to endocrine therapy, with benefit differing by menopausal status even at similar clinical risk; the epidemiologic principle that surgical exposure to opioids/sedative-hypnotics carries a measurable, risk-factor-dependent probability of converting a previously naive patient into a persistent user; and the reproductive oncology principle that pregnancy after cancer treatment does not independently increase disease recurrence risk, though cancer treatment itself can reduce fertility and elevate certain obstetric/neonatal risks. These fall within medical oncology's evidence-based, risk-stratified approach to treatment selection and survivorship care, integrating biomarker-guided therapy de-escalation, perioperative risk management, and quality-of-life/survivorship outcomes.
This concept covers evidence-based decision-making principles in breast cancer oncology: the use of validated genomic recurrence-risk assays (multi-gene expression assays) to stratify which patients …